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RESEARCH ARTICLE
Biomimetic synthesis of proline-derivative templated mesoporous silica
for increasing the brain distribution of diazepam and improving the
pharmacodynamics of nimesulide
Heran Lia, Jianxin Wanga, Jialiang Congb, Chen Weib, Jing Lia, Hongzhuo Liub, Sanming Lib and Mingshi Yanga,c
aWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China; bSchool of Pharmacy, Shenyang Pharmaceutical
University, Shenyang, China; cFaculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark
ABSTRACT
Herein a new kind of proline-derivative templated mesoporous silica with curved channels (CMS) was
biomimetically synthesized and applied as carrier to improve the drug dissolution and bioavailability of
hydrophobic diazepam (DZP) and nimesulide (NMS). Drugs can be incorporated into CMS with high
efficiency; during this process, they successfully transformed to amorphous phase. As a result, the dis-
solution rate of DZP and NMS was significantly improved. Biodistribution study confirmed that CMS
converted DZP distribution in mice with the tendency of lung targeting and brain targeting. At 45min
postadministration, the concentrations of DZP in plasma, lung and brain were 8.57-fold, 124.94-fold
and 19.55-fold higher from 1:3 DZP/CMS sample than that of pure DZP sample, respectively. At 90min
postadministration, the content of DZP in brain was 62.31-fold higher for 1:3 DZP/CMS sample than
that of pure DZP. Besides, the anti-inflammatory and analgesic effects of 1:3 NMS/CMS were systematic
evaluated using mouse ankle swelling test (MAST), mouse ear swelling test (MEST) and mouse writhing
test (MWT). The results indicated that after incorporating into CMS, the therapeutic effects of NMS
were obviously improved, and the inhibition rates of 1:3 NMS/CMS in all pharmacodynamics tests
varied from 102.2% to 904.3%.
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1. Introduction
In the area of clinical work, the low solubility of the drugs
causes a series of problems, such as low bioavailability, insuf-
ficient clinical outcomes and dose escalation due to the poor
absorption in the gastrointestinal tract after oral administra-
tion (Dolinina et al., 2016; Maleki & Hamidi, 2016). However,
nearly 2/5 of the marketed immediate-release oral drugs are
practically insoluble, including diazepam and nimesulide
(Zhang et al., 2015). Diazepam is a positive allosteric modula-
tor of the GABA type A receptors belonging to the benzodi-
azepine family which is very slightly soluble in water, and is
commonly used for the treatment of anxiety, muscle spasms,
seizures, etc. (Riss et al., 2008; Giacomini et al., 2016).
Nimesulide is a kind of non-steroidal anti-inflammatory drug
(NSAID) which can be classified as BCS II (Kress et al., 2016).
It works by blocking the production of prostaglandins, inhib-
iting COX-2 selectively, and is developed for the treatment of
acute pain (short term), and primary dysmenorrhea (period
pains) (Luo et al., 2015). In these cases, improving the solubil-
ity and controlling the drug release behavior are the core
strategies to increase the oral bioavailability of poorly water-
soluble drugs. Many efforts have been made to overcome
the low bioavailability of the poorly water-soluble drugs,
such as co-solvents (Jogunola et al., 2016), complexation
(Zhang et al., 2017), salification (Fini et al., 2012), microniza-
tion (Fu et al., 2013), solid dispersion (Maher et al., 2016), ves-
icle (Yan et al., 2016), micelle (Liu et al., 2017), cyclodextrin
(Loftsson & Brewster, 2012), etc. (Meng et al., 2017). With the
development of technology, materials were developed into
nanoscale level and were found applications in many fields
including drug delivery, catalysis, sensors, adsorption and
separation (Goscianska et al., 2015; Li et al., 2015c). Since the
M41S family was first discovered in the early 1990s, mesopo-
rous silica has attracted increasing interest because of their
unique properties such as relatively large surface area and
pore volume, excellent pore structure and rich morphology,
uniform and adjustable size and in vivo biosafety, and has
been proved to be promising candidates for biomedical
applications and drug delivery (Putz et al., 2015; Wang et al.,
2015; Guha et al., 2016). Compared with traditional methods,
the silica-based mesoporous materials have additional advan-
tages to be considered as a novel drug carrier. Firstly, the
well-developed nanometer-sized pores effectively limit the
crystallization of drug and keep the drug in an amorphous
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state to increase the solubility of drug in water (Hu et al.,
2015). Secondly, the structural features of mesoporous
silica nanoparticles provide hydrophobic microenvironment
which enhances the stability of drugs and is well suited for
drug loading (Mekaru et al., 2015). Thirdly, the excellent bio-
logical compatibility and safety of silicon materials enable
their application as novel drug delivery systems (Xie et al.,
2016).
Intricate nanostructure and nanopatterning with precise
control usually appeared in diatoms and sponges (Naik et al.,
2003; Ford & Yang, 2007). Biominerals often show hierarchical
organization ranging from nanoscale to microscale (Jin &
Yuan, 2006). During the biomineralization process, organisms
are formed within their cell walls and reproduced generation
after generation (Zhao & Su, 2012). Biomimetic synthesis of
mesoporous silica has become one of the current topics in
silica materials since biomineralization is a bottom-up process
occurred at ambient condition and is genetically controlled
by specialized biomacromolecules including polysaccharides,
polypeptides and amino acid derivatives (Naik et al., 2003;
Jin & Yuan, 2006). For example, controlled formation of
arched and elongated biosilica structures was synthesized by
Rajesh et al., using a synthetic peptide (Naik et al., 2003).
Folate-templated mesoporous silica was obtained by using
folate supramolecular templates and it grew followed a
standard nucleation and growth mechanism (Atluri et al.,
2013). Besides, aspartic acid block copolymer-imprinted mes-
oporous silica which can be used for chiral separation was
successfully obtained by Paik et al., by using amphiphilic
molecules composed of D/L-aspartic acid and PEG (Paik et al.,
2010). A novel nanoporous silica xerogel was prepared using
polyethyleneimine with biomimetic method and used as
drug carrier to investigate the controlled release behavior of
this material (Li et al., 2014).
In the present study, mesoporous silica nanosphere with
curved channels was biomimetically synthesized based on
solgel method by using synthesized surfactant N-palmitoyl-L-
proline as template, 3-aminopropyltriethoxysilane (APTES) as
CSDA and tetraethoxysilane (TEOS) as the main inorganic
source. The morphology and structural features of CMS were
investigated using transmission electron microscopy (TEM),
scanning electron microscopy (SEM), X-ray diffraction (XRD)
and nitrogen adsorption/desorption measurement. Diazepam
(DZP) and nimesulide (NMS) were selected as model drugs,
and they were loaded into CMS according to the solvent
deposition method. The drug loading and release behaviors
of model drugs with CMS as carries were deeply studied to
explore the controlled release functions of CMS. The drug
crystalline state was systemically characterized using X-ray
diffraction (XRD), differential scanning calorimetry (DSC), ther-
mal gravity analysis (TGA) and Fourier transform infrared
spectrometer (FTIR). Biodistribution study of samples after
oral administration was performed to confirm the in vivo
behavior of CMS. Besides, the anti-inflammatory effect of
NMS/CMS was systematically evaluated. In particular, the bio-
distribution and pharmacodynamic studies of drug/CMS sam-
ples were compared with that of the samples composed of
drugs and the commercially available silica-based mesopo-
rous material MCM41.
2. Experimental
2.1. Materials
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
(EDCI), 1-hydroxybenzotriazole (HOBT), dimethylformamide
(DMF) and 4-(dicyanomethylene)-2-methyl-6-(4-dimethylami-
nostyryl)-4H-pyran (DCM) were purchased from Shanghai
Jinjinle Industrial Co., Ltd. (Shanghai, China). 3-aminopropyl-
triethoxysilane (APTES) and k-carrageenan were purchased
from Chengdu Xiya Chemical Technology Co., Ltd. (Chengdu,
China). Palmitic acid, L-proline methyl ester and tetraethoxysi-
lane (TEOS) were purchased from Yangzhou Baosheng
Biochemical Co., Ltd. (Yangzhou, China). MCM41 (average
pore diameter: 3–5 nm; particle size: 200–300 nm) was
obtained from Suzhou Jiedi Nano Technology Co., Ltd.,
(Suzhou, China). Diazepam and carbamazepine were pro-
duced by Zhengzhou Ancheng Biological Technology Co.,
Ltd. (Zhengzhou, China). Nimesulide was obtained from
Wuhan Dinghui Chemical Co., Ltd. (Wuhan, China). Double
distilled water was prepared by ion exchange and used in all
experiments.
2.2. Synthesis of N-palmitoyl-L-proline
In a typical run, 0.33 g L-proline methyl ester hydrochloride
was dissolved in 10ml TMF, to which 1ml triethylamine was
added dropwise under stirring. After 20min, palmitic acid
(0.51 g), EDCI (0.46 g) and HOBT (0.23 g) were added and
stirred for another 20min. Then, 2ml DCM was introduced to
the system and the mixture was transferred to an oil bath at
60 C, and the reaction was supervised by thin layer chroma-
tography (TLC) until brown liquid was obtained. Then, the
mixture was evaporated to remove the organic phase and
carefully washed by a saturated aqueous solution of NaHCO3
and water. After precipitation, the crude obtained was fil-
tered, dried, crushed and weighted without recrystallization
(because of the low melting point).
N-palmitoyl-L-proline was prepared by hydrolyzing of
N-palmitoyl-L-proline methyl ester. In detail, N-palmitoyl-L-
proline methyl ester was dissolved in 100ml mixture solution
composed of 70% ethyl alcohol, 30% water (v/v) and 12.39 g
NaOH under stirring for about 6 h. Then, the N-palmitoyl-L-
proline obtained was separated from organic solvent using
reduced pressure distillation, adjusted pH to 2–3 by HCl,
filtered, washed, dried and weighted.
2.3. Preparation of CMS
CMS was synthesized by a procedure established by our
laboratory using APTES as CSDA and TEOS as silica source.
Typically, 0.43 g of N-palmitoyl-L-proline was dispersed in
10ml water at 80 C under stirring. Afterwards, 10ml NaOH
was added dropwise and the system was cooled to 25 C.
After stirring for at least 1 h, a mixture of APTES (0.24ml) and
TEOS (1.57ml) was introduced to the solution, and the sys-
tem was stirred until milky white turbid solution was
obtained. Then, the mixture was left at ambient condition
statically for 24 h. After that, the precipitation was separated
DRUG DELIVERY 1087
D
ow
nl
oa
de
d 
by
 [C
op
en
ha
ge
n U
niv
ers
ity
 L
ibr
ary
] a
t 0
2:2
7 2
5 S
ep
tem
be
r 2
01
7 
by centrifuge, washed several times with ethanol and deion-
ized water, dried, grinded and finally calcined at 550 C for
6 h with a slow heating rate.
2.4. Drug loading process
The solvent deposition method was carried out to load diaze-
pam (DZP) and nimesulide (NMS) into CMS, respectively. In
detail, DZP was first dissolved in acetone to get a high-con-
centration solution (10mg/ml). DZP loaded to CMS was
achieved by adding certain amount of CMS into the solution
of DZP at a series of drug/carrier ratios (2:1, 1:1, 1:2 and 1:3,
w/w). Then, the system was sealed and left under ambient
condition for at least 24 h with gentle stirring. After that, the
mixture was washed with methanol to remove the drugs
adsorbed on the surface of CMS and dried under vacuum.
The products were named as 2:1 DZP/CMS, 1:1 DZP/CMS, 1:2
DZP/CMS and 1:3 DZP/CMS, respectively. The drug loading
contents of DZP/CMS samples were determined by taking 5mg
of DZP/CMS samples and extracting DZP completely using
ethanol under the treatment of ultrasound. Finally the concen-
tration of DZP was measured by ultraviolet (UV) spectroscopy
(UV-1750, Shimadzu, Japan) at a wavelength of 240nm.
NMS/CMS samples were prepared by the same method
and denoted as 2:1 NMS/CMS, 1:1 NMS/CMS, 1:2 NMS/CMS
and 1:3 NMS/CMS, respectively. In particular, the NMS loading
process should be operated in the darkroom. Drug loading
content was measured by taking 5mg of NMS/CMS samples
and ultrasonically extracting the loaded NMS completely using
NaOH (0.05mol/L). Finally, the content of NMS loaded was
analyzed by UV spectroscopy at the wavelength of 393nm.
DZP/MCM41 samples and NMS/MCM41 samples were also
prepared by solvent evaporation method at the drug/carrier
ratio of 1:3 (w/w) and were referred to as 1:3 DZP/MCM41
and 1:3 NMS/MCM41, respectively.
2.5. Characterizations
TEM images and SEM images of the prepared CMS were
obtained using a TEM instrument (Tecnai G2-F30, FEI, the
Netherlands) and a SEM instrument (JSM-6510A, JEOL,
Japan), respectively. The nitrogen adsorption and desorption
analysis was carried out using an adsorption analyzer (Vsob-
2800 P, China) at 196 C to get the information of the sur-
face area and pore volume of CMS. The specific surface area
(SBET) was estimated using the Brunauer–Emmett–Teller (BET)
method. Barrett–Joyner–Halenda (BJH) method was used to
calculate the pore size distribution (PSD) from the corre-
sponding desorption branch of the ad/desorption isotherm.
The total pore volume (Vt) was derived from N2 adsorption at
the relative pressure of 0.99. FTIR study (Spectrum 1000,
PerkinElmer, Waltham, MA) and in situ FT-IR study (IR Tracer-
100, Shimadzu, Japan) were carried out to obtain the struc-
tural information and the interaction between drug and
carrier. Prior to the study, samples were carefully mixed with
dried KBr and crushed to prepare KBr disks. XRD patterns of
samples were acquired using an X-ray diffractometer
(EMPYREAN, PANalytical B.V., the Netherlands) at 30mA and
30 kV with a Ni-filtered CuKa line as the source of radiation.
DSC curves were generated on a differential scanning calor-
imeter (DSC, Q1000, TA Instrument, New Castle, DE). Each
sample was heated from 20 to 200 C with a heating rate of
5 C/min under a nitrogen flow. TGA analysis was performed
on DTA-TG instrument (DTG-60, Shimadzu, Japan) from 50 to
550 C at a heating rate of 10 C/min.
2.6. In vitro release behavior
Dissolution studies of samples were carried out according to
a USP II paddle method at 37 C with a stirrer rotation speed
of 50 rpm in a dissolution apparatus (ZRD6-B, Shanghai
Huanghai Medicament Test Instrument Factory, Shanghai,
China). Pure DZP (4mg) and DZP/CMS samples (containing
4mg DZP) were, respectively, exposed to 250ml of deionized
water. At predetermined time intervals, 5ml samples were
taken out and replaced by fresh medium immediately. Then,
samples were passed through a 0.22lm membrane filter and
were transferred to UV/Vis analysis at the wavelength of
240 nm. Besides, the dissolution of DZP and 1:3 DZP/CMS
was also investigated in the medium of simulated gastric
fluid (SGF, pH 1.0) and simulated intestinal fluid (SIF pH 6.8)
to further evaluate the in vitro release behavior of samples.
Samples containing 5mg NMS were put into 250ml phos-
phate buffer solutions (PBS, pH 7.8) at 37 C. Taking, process-
ing and analyzing of samples were the same as the
dissolution studies of DZP and the absorbance was measured
at 393 nm.
2.7. Animals
All animal experiments were approved by the Shenyang
Pharmaceutical University Animal Care and Use Committee
(Liaoning, China). Animals received care in compliance with
the guidelines for the Care and Use of Laboratory Animals.
2.8. Biodistribution of diazepam
2.8.1 Experimental design
The biodistribution of the test silica formulation (1:3 DZP/
CMS) was compared with that of the pure DZP and the drug
loading samples composed of DZP and commercially avail-
able silica-based carrier MCM41. 24 male SPF-grade Kunming
mice weighing 18–22 g were randomly assigned into three
groups: DZP group, 1:3 DZP/CMS group and 1:3 DZP/MCM41
group. Before the experiment, animals were fasted overnight
with free access to water. Samples equivalent to 1mg DZP
were suspended in normal saline and were provided to mice
by intragastric administration. At 45min and 90min after oral
administration, blood samples were taken by removing eye-
ball. Then, animals were sacrificed, and major organs includ-
ing the brain, heart, liver, kidney, spleen and lungs were
rapidly collected, weighed, disrupted in a manual homogen-
ate instrument, extracted with cold physiological saline, cen-
trifugated twice at 6000 rpm for 8min to get supernatant
and frozen at 20 C. The content of DZP in blood and
organs was measured by high-performance liquid chroma-
tography (HPLC).
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2.8.2. Sample preparation and HPLC analysis of DZP
Firstly, 20 ll of internal standard solution (carbamazepine,
20 lg/ml) and 200 ll of alkaline liquid (NaOH, 0.5mol/L)
were added to 200 ll of biological samples and mixed by
vortex mixer (3min). Then, 2.6ml of extraction solvent
(diethyl ether) was introduced and the mixture was further
vortexed for 5min. After centrifugation at 5000 rpm for
10min, the organic phase (2ml) was carefully removed and
evaporated to dryness at 40 C under a gentle stream of N2.
Then, the dried residue was reconstituted with 100 lL
mobile phase, vortexed, centrifuged, and delivered to HPLC
analysis (20 ll).
The HPLC method was established to measure the con-
centrations of DZP in blood and organs. The HPLC system
was equipped with a Hitachi 10-AT pump and a UV detector
which was set at 254 nm. The separation was carried out on
a Thermo ODS-2 Hypersil C18 column (250mm 4.6mm,
5mm, Waltham, MA) preceded by a JanuSep C18 pre-column
(Benxi, China). The flow rate was kept at 1ml/min with a
mobile phase consisted of methanol and water (75:25, v/v).
The column temperature was maintained at 25 C. The DZP
concentrations were calculated by internal standard method.
2.9. Pharmacodynamic studies of NMS
2.9.1. Mouse ankle swelling test
A swelling inhibition study comprised of 18 male Sprague
Dawley rats weighted 180–220 g was carried out to compare
the anti-inflammatory profile of 1:3 NMS/CMS (NMS/CMS
middle-dose group) vs. NMS/MCM41 (1:3 NMS/MCM41
group). Normal saline (NS group) and pure NMS (NMS group)
were given to rats and served as negative control and posi-
tive control, respectively. Rats in NS group were administered
orally of normal saline only, and rats in other groups were
administered orally at a dose equivalent to 25mg/kg NMS.
To evaluate the effect of dosage, another two groups of rats
were exposed to half and twice of the dose in NMS/CMS
middle-dose group which equaled to 12.5mg/kg and
50mg/kg of NMS and denoted as the NMS/CMS low-dose
group and the NMS/CMS high-dose group, respectively.
At 30min postadministration, 0.1ml k-carrageenan (1%, w/v)
was injected to the right ankle area of each rat to induce
acute inflammatory models. Then, the circumference of right
ankle was measured at 0.5 h, 1 h, 1.5 h, 2 h, 3 h and 4 h after
injection of k-carrageenan. It should be noticed that, before
the test, the initial circumference of right ankle of each rat
was measured and the swelling degree was evaluated by the
variation of ankle circumference. The repression rate and
the swelling rate of the ankle swelling were calculated using
the following Equations (1) and (2), respectively:
Repression rate %ð Þ
¼ ðct  c0Þnegative control  ðct  c0Þtestðct  c0Þnegative control  ðct  c0Þpositive control
 100 (1)
Swelling rate %ð Þ ¼ ct  c0
c0
 100 (2)
where c0 is the initial circumference and ct is the circum-
ference measured at different time points.
2.9.2. Mouse ear swelling test
The mouse ear swelling test was developed to further evalu-
ate the swelling inhibition potential of NMS/CMS. In detail,
16 male Kunming mice weighing 18–22 g were randomly div-
ided into four groups (n¼ 4): NS group (negative control
group), NMS group (positive control group), NMS/CMS group
(1:3 NMS/CMS) and NMS/MCM41 group (1:3 NMS/CMS).
Samples containing 0.6mg NMS were suspended in normal
saline and imposed to mice in all groups by intragastric
administration. Mice in NS group were exposed to normal
saline only. At 30min after administration, 0.1ml xylene was
applied on each side of the left ear of mice, and the right
ear regarded as a reference was left untreated. After 50min,
mice were executed, both ears were removed, and tissues
with diameter of 0.6 cm were cut off by hole punch. The
weight of the tissues cut from left and right ears was meas-
ured by electronic scale. The repression rate and the degree
of ear swelling were, respectively, expressed as:
Repression rate %ð Þ
¼ ðwL  wRÞnegative control  ðwL  wRÞtestðwL  wRÞnegative control  ðwL  wRÞpositive control
 100
(3)
Swelling rate %ð Þ ¼ wL  wR
wR
 100 (4)
where wL is the weight of tissue cut from the left ear and
wR is the weight of tissue cut from the right ear of the same
mice.
2.9.3. Mouse writhing test
The antinociceptive effects of NMS/CMS and NMS/MCM41
were investigated and compared in mouse writhing test. 16
mice were randomly assigned into four groups (n¼ 4): NS
group (negative control group), NMS group (positive control
group), NMS/CMS group (1:3 NMS/CMS) and NMS/MCM41
group (1:3 NMS/MCM41). Mice were orally administered with
the samples which were equivalent to 0.6mg NMS. At 1 h
postadministration, mice were intraperitoneally injected with
0.4ml acetic acid 0.4% (v/v) to induce writhing and were indi-
vidually housed in a mouse cage (20 30 12 cm).
Afterwards, the number of writhes (a writhe was account as
abdominal constriction or stretching of at least one hind
limb) for each mice was recorded within 20min postinjection.
The repression rate of the test formulations was expressed as:
Repression rate %ð Þ ¼ nnegative control  ntest
nnegative control  npositive control  100
(5)
where n is the number of writhes recorded from each
mice.
2.10. Statistical analysis
All in vitro studies were performed in triplicate and the data
were expressed as mean± SD. The in vivo results are
expressed as the means ± SD. Statistical analysis was analyzed
by Student’s t-test or one-way analysis of variance followed
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by Dunnet’s t-test to identify levels of significance between
the groups. Statistical significance was set as p< .05.
3. Results and discussion
3.1. Formation mechanism of CMS
CMS was successfully synthesized upon a co-structure direct-
ing agent (CSDA) method through the solgel reaction. In the
present work, N-palmitoyl-L-proline was served as template,
TEOS was used as the main silica source and APTES was
employed as structure directing agent. As described in Figure 1,
during the synthesis process, alkoxysilane sites of APTES
polymerized with TEOS to form framework; meanwhile, posi-
tively charged ammonium sites of APTES electrostatically
interact with negatively charged part of the N-palmitoyl-L-
proline (Li et al., 2015b). The curved mesostructure was initi-
ated by the dynamic self-assembly of N-palmitoyl-L-proline
and imprinted along with the process of silica deposition. It
should be mentioned that, during the synthesis process,
amines actively catalyzed the condensation of silica precur-
sors; thus, the synthesis can be classified to biomimetic syn-
thesis (Naik et al., 2003; Li et al., 2015b).
3.2. Characterization of CMS
As can be seen in Figure 2, CMS particles were nanospheres
with shell–core structure and were about 200–300 nm in
diameter. A large number of disordered curved channels
were clearly visible with wormhole arrangement. Figure 2(D)
showed the nitrogen adsorption–desorption isotherm and
pore size distribution curve of CMS. It can be seen that CMS
exhibited a type IV feature with a capillary condensation
step, indicating the presence of mesopores (Nakanishi et al.,
2014; Li et al., 2016). The average pore size estimated by BJH
method was 3.42 nm, the BET surface area of CMS was
568.27 m2/g, and the total pore volume was found to be
0.75 cm3/g. In the FTIR spectrogram of CMS (Figure 3(A)),
Si–O–Si bending vibration at 466.1 cm1 and Si–O–Si anti-
symmetric stretching vibration at 1096.1 cm1 can be
detected, indicating the successful synthesis of silica materi-
als (Nakanishi et al., 2014; Finlay et al., 2015; Li et al., 2015a).
Moreover, the XRD (Figures 2(E), 4(A)) and DSC patterns
(Figure 4(C,D)) indicated that CMS was a kind of amorphous
material with mesoporous structure (Finlay et al., 2015;
Hashemikia et al., 2016).
3.3. Drug loading content
As summarized in Table 1, the drug loading content of CMS
was very high, and only a small proportion of drug was lost
during the loading process. The loading content of DZP
and NMS into CMS was decreased with the increasing pro-
portion of CMS. For both drugs, the drug loading capacity
of CMS (26.69% for 1:3 DZP/CMS and 23.06% for 1:3 NMS/
CMS) was higher than the drug loading capacity of MCM41
(21.17% for 1:3 DZP/MCM41 and 20.57% for 1:3 NMS/
MCM41). The results suggested stronger interactions
between drugs and CMS, indicating that CMS could load
drugs with high efficiency, which was an important feature
to be extensively used as carrier of sustained-release and
controlled-release preparation.
Figure 1. Schematic illustration of synthesize routes of N-palmitoyl-L-proline (A,B) and CMS (C–E). (A) Dehydration–condensation reaction catalyzed by EDCI and
HOBT; (B) ester hydrolysis reaction; (C) self-assembly process; (D) silica deposition procedure; (E) removal of temples by calcination; (F) drug loading process.
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3.4. Physical state of drug-loaded samples
3.4.1. FTIR
Structural information of drug-loaded samples was illustrated
by FTIR. As shown in Figure 3(A), DZP showed aromatic
hydrocarbon peak at 3055 cm1, which corresponded to C–H
stretching vibration of benzene ring, and peaks at 2911 cm1
and 1483 cm1 belonging to the C–H stretching vibration
and N–H bending vibration of the –CH3 groups,
respectively (Mielcarek et al., 2011; Yamamoto et al., 2016;
Bedard et al., 2017). After loading into CMS, most of the char-
acteristic peaks of DZP disappeared, suggesting that DZP was
successfully incorporated into CMS. Meanwhile, hydrogen
bonding could be formed between the silanol groups of CMS
and the carbonyl functions of DZP, which resulted in a red
shift and a peak broadening of the peak at 1685 cm1 rela-
tive to the C¼O group (Mielcarek et al., 2011).
More details are announced in the in situ FITR spectra of
DZP and 1:3 DZP/CMS. As can be seen from Figure 3(C), the
Figure 2. (A–C) TEM images of CMS, (B) is the local structure of (A); (C) is the amplifying image of (A); (D) nitrogen adsorption/desorption isotherm and pore size
distribution curve of CMS; (E) SAXD pattern of template-free CMS; (F–G) SEM images of CMS.
Figure 3. FTIR spectra of samples (A), and in situ FTIR spectra of CMS (B), DZP (C), 1:3 DZP/CMS (D), NMS (E) and 1:3 NMS/CMS (F).
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intensity of the main characteristic peaks of DZP decreased
gradually with the increasing temperature. Furthermore,
peaks in the region of 1100–900 cm1 disappeared gradually.
Peaks at 1340 cm1 and 1323 cm1, which were assigned to
in-plane C–H bending vibration of the benzene ring, had
shifted to the lower wavenumbers, indicating the p–p inter-
actions between benzene rings (Moros et al., 2007). Both the
spectra of DZP and 1:3 DZP/CMS (Figure 3(D)) showed red-
shift of the wavenumber of carbonyl group peak from 1685
to 1681 cm1, and from 1683 to 1678 cm1, respectively.
However, the intensity of peaks in situ FTIR spectra of 1:3
DZP/CMS changed slightly with temperature.
FTIR spectra of NMS before and after drug loading were
also investigated and were shown in Figure 3(A). The charac-
teristic peaks of the aromatic secondary amine can be
observed, including the peak at 3283 cm1 that attributed to
the N–H stretching vibration and the peak at 1317 cm1
belonging to the stretching vibration of C¼N (de Paiva
et al., 2012). However, in the spectra of 1:3 NMS/CMS, the
peaks of benzene ring and secondary amine decreased sig-
nificantly. It seemed that, NMS was successfully entered into
the curved mesoscopic channels of CMS and hydrogen
bonds were formed between the secondary amine groups of
NMS and silanol groups of CMS during the drug loading pro-
cess (Ramos & Diogo, 2016). The in situ FTIR spectra of NMS
(Figure 3(E)) showed blueshift of the wavenumber of sulfonyl
group characteristic peaks from 1155 to 1159 cm1, which
was related to the weakening of the S¼O bond. Besides, the
redshifts of the absorption bands from 1342 to 1340 cm1
and from 1282 to 1280 cm1 with decrease of intensity were,
respectively, identified as the stretching of NO2 group and
C–N group, indicating the consumption of intermolecular
interaction (Huerta et al., 2015; Ramos & Diogo, 2016).
However, in comparison with NMS, peaks belonging to the
NO2 group and C–N group in the in situ spectra of 1:3 NMS/
CMS (Figure 3(F)) showed no shift of wavenumber during the
heating process, indicating a more stable environment.
3.4.2. XRD and DSC
The physical states of DZP and NMS before and after drug
loading process were determined by XRD and DSC, respect-
ively. As shown in Figure 4(A), CMS comprised a broad band,
characterized as amorphous single-phase material. The dif-
fraction patterns of pure DZP and pure NMS were highly
crystalline in nature as indicated by the numerous peaks.
However, after drug loading process, the diffraction peak of
1:3 DZP/CMS sample showed amorphous broad peak, sug-
gesting that DZP was loaded into CMS in amorphous state.
Similar situation was found in the case of 1:3 NMS/CMS sam-
ple, and no crystalline NMS diffraction peak was detected. It
seemed that the twisty mesopores of CMS and the limited
living space of drugs prevented the crystallization of drugs,
which were evidenced by the absence of crystalline peaks
(Verheyen et al., 2001; Singh et al., 2015).
The DSC trace conducted on CMS was almost a smooth
line with no melting point depression (Figure 4(C)). The DSC
thermograms of DZP and NMS possessed single melting
Figure 4. (A) XRD patterns of (A) DZP; (B) physical mixture of DZP/CMS (1:3, w/w); (C) 1:3 DZP/CMS; (D) CMS; (B) XRD patterns of (A) NMS; (B) physical mixture of
NMS/CMS (1:3, w/w); (C) 1:3 NMS/CMS; (D) CMS; (C) DSC thermograms of (A) DZP; (B) physical mixture of DZP/CMS (1:3, w/w); (C) 1:3 DZP/CMS; (D) CMS; (D) DSC
thermograms of (A), NMS; (B) physical mixture of NMS/CMS (1:3, w/w); (C) 1:3 NMS/CMS; (D) CMS; (E) TGA-DTA thermograms of DZP, 1:3 DZP/CMS and CMS; (F)
TGA-DTA thermograms of NMS, 1:3 NMS/CMS and CMS.
Table 1. Drug loading capacity (%) of samples.
Sample
Drug loading
capacity (%) Sample
Drug loading
capacity (%)
2:1 DZP/CMS 57.31 ± 1.07 2:1 NMS/CMS 63.63 ± 1.56
1:1 DZP/CMS 49.80 ± 2.14 1:1 NMS/CMS 49.36 ± 1.28
1:3 DZP/CMS 33.45 ± 0.87 1:2 NMS/CMS 31.55 ± 0.27
1:3 DZP/CMS 26.69 ± 0.92 1:3 NMS/CMS 21.17 ± 0.94
1:3 DZP/MCM41 23.06 ± 1.78 1:3 NMS/MCM41 20.57 ± 1.22
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peak at 149.5 C (Figure 4(C)) and 134.5 C (Figure 4(D)),
respectively (Nunes et al., 2016; Yamamoto et al., 2016;
Bedard et al., 2017). The melting peaks of crystallographic
DZP and NMS in the physical mixture of DZP/CMS (1:3, w/w)
and NMS/CMS (1:3, w/w) can be easily detected with reduc-
tions of peak intensity. However, the DSC curves of 1:3 DZP/
CMS and 1:3 NMS/CMS showed no melting peak for drugs,
suggesting that DZP and NMS were existed in amorphous
state. It should be noticed that DSC results were in agree-
ment with XRD findings. Therefore, based on XRD and DSC
results, after loading DZP or NMS into CMS, crystal form of
drugs had been successfully converted to amorphous state.
Figure 4(E,F) showed the TGA and DTA curves of 1:3 DZP/
CMS, 1:3 NMS/CMS and CMS, respectively. The DTA results of
1:3 DZP/CMS and 1:3 NMS/CMS were inconsistent with the
DSC results when the temperature was lower than 200 C,
and NMS began to decompose when the temperature was
higher than 450 C. Besides, 1:3 DZP/CMS sample had under-
gone a two-stage decomposition at 270 C and 500 C,
respectively. Meanwhile, the TGA curve of CMS was almost a
horizontal line with a slightly weight loss (ca. 4.67%), which
was related to the water adsorbed into CMS. As a result
of the adsorbed water, the weight loss of 1:3 DZP/CMS
(ca. 68.69%) and 1:3 NMS/CMS (ca. 71.09%) was also a little
higher than the drug loading content measured before.
3.5. In vitro drug release study
A series of DZP/CMS samples were prepared, the release
behaviors of them were studied, and the release profiles
were presented in Figure 5(A). The result confirmed that
DZP/CMS samples released much faster than the pure DZP.
Their cumulative release percentage was more than 80%
within 24 h, compared to that of pure DZP which released
only 66.75%. Among them, best result came out from 1:3
DZP/CMS sample, which could release 87.25% of drug within
24 h. It should be noted that DZP release rate was deter-
mined by the drug/carrier weight ratio, and it increased with
the increasing CMS proportion due to the inhibition of crys-
tallization. In detail, the limitation of living space and the
hydrophilic microenvironment of the carrier allowed the
amorphization of the drug, which observably increased
the solubility of poorly water-soluble drugs as a result
of the higher energy state (Li et al., 2015a). On the other
hand, the crystal growth of drug can be restricted by the
Figure 5. In vitro release profiles of samples. (A) The release profiles of DZP, 2:1 DZP/CMS, 1:1 DZP/CMS, 1:2 DZP/CMS and 1:3 DZP/CMS in water; (B) the release
profiles of DZP and 1:3 DZP/CMS in SGF; (C) the release profiles of DZP and 1:3 DZP/CMS in SIF; (D) the release profiles of NMS, 2:1 NMS/CMS, 1:1 NMS/CMS, 1:2
NMS/CMS and 1:3 NMS/CMS in PBS.
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very porous nature of CMS, which enhanced the dissolution
rate of drug (Nakanishi et al., 2014).
To further study the influence of pH on the dissolution
behavior of 1:3 DZP/CMS sample, in vitro drug release study
was performed in SGF medium (pH 1) and SIF medium (pH
6.8), respectively. As can be seen in Figure 5(B,C), the dissol-
ution rate of DZP can be obviously improved after loading
into CMS in both SGF and SIF. However, it is worth mention-
ing that the drug release rate of 1:3 DZP/CMS in SGF was a
little faster than that in SIF and in water with a burst release,
and the final release ratio was higher than 95%. Besides,
pure DZP also presented faster release in SGF rather than
SIF and water (87.73% in SGF, 69.32% in SIF and 66.75%
in water). The difference of release behavior may be
attributed to the difference of saturated solubility of DZP in
different dissolution media, which was 6.6mg ml1 in
SGF, 0.046mg ml1 in SIF and 0.054mg ml1 in water
(Aman-Pommier & Degobert, 2015).
The dissolution profiles of pure NMS, 2:1 NMS/CMS, 1:1
NMS/CMS, 1:2 NMS/CMS and 1:3 NMS/CMS were also investi-
gated, and the results were presented in Figure 5(D). It can
be seen from the magnification of the releasing curve, during
the first 1 hour, NMS/CMS sample released faster than the
pure NMS, and the release rate increased with the increasing
proportion of the carrier. However, as indicated by the accu-
mulative release percentage, 2:1 NMS/CMS, 1:1 NMS/CMS
and 1:2 NMS/CMS exhibited dissolution patterns similar to
the pure NMS. They all released about 95% of CMS within
24 h (93.1% for pure NMS, 96.1% for 2:1 NMS/CMS, 94.1% for
1:1 NMS/CMS and 93.7% for 1:2 NMS/CMS). Between them,
1:3 NMS/CMS showed improved release behavior in both rate
and accumulative release percentage compared with pure
NMS. These result demonstrated that, in the case of NMS/
CMS, the improvement of dissolution rate can be attributed
to the limited particle size and the conversion of crystalline
state of NMS into amorphous phase but not the present of
CMS. And the dissolution profile of drug can be regulated
and controlled by mixing with different ratio of carrier.
3.6. Biodistribution of DZP
The concentration of DZP in blood and organs was measured
by HPLC method at 45min and 90min after oral medication.
As compared with 1:3 DZP/CMS, the DZP biodistribution after
treatment of 1:3 DZP/MCM41 was also investigated due to
the fact that MCM41 was a kind of mesoporous silica carrier
widely used in drug sustained and controlled release area. In
the present study, MCM41 with average particle size of
250 nm was chosen to eliminate the effect of size. Moreover,
the distribution of pure DZP after oral administration was
also determined and regarded as a reference.
As shown in Figure 6, at 45min postadministration, DZP
distributed themselves spatially in different tissues, and
remarked difference can be observed between the three
groups. In detail, 1:3 DZP/CMS sample had a higher drug dis-
tribution in blood, lung and brain and lower drug content in
heart, whereas 1:3 DZP/MCM41 sample had a higher distribu-
tion in heart, spleen and kidney compared with their
counterparts. The drug plasma concentrations of 1:3 DZP/
CMS sample and 1:3 DZP/MCM41 sample were 8.57-fold and
7.94-fold higher than pure DZP sample, respectively. In lung,
the content of DZP from 1:3 DZP/CMS sample was 124.94-
fold and 1.67-fold higher than that of pure DZP and 1:3 DZP/
MCM41 sample, respectively. Besides, the distribution of drug
in brain from 1:3 DZP/CMS sample was 19.55-fold of that
from DZP sample and 5.03-fold of that from 1:3 DZP/MCM41
sample. Meanwhile, in heart and spleen, the drug content of
1:3 DZP/MCM41 sample was 1.81-fold and 3.37-fold of that
of DZP sample, and 2.11-fold and 1.96-fold of that from 1:3
DZP/CMS sample, respectively. It seemed that, after adminis-
tration, 1:3 DZP/CMS sample and 1:3 DZP/MCM41 sample
showed higher bioavailability in blood and organs as com-
pared to pure DZP.
At 90min postadministration, all three samples had a
comparable decrease of drug content in blood, heart and
live. Compared to the drug concentration at 45min postad-
ministration, all samples had 48%–58% decrease in heart and
26%–56% decrease in liver, respectively. In kidney and
spleen, the DZP content of 1:3 DZP/MCM41 sample suffered
greatly attenuation and decreased to a lower level (about
17% and 15% of the drug content at 45min postadministra-
tion, respectively). Meanwhile, the plasma concentration of
DZP from 1:3 DZP/CMS sample was 2.71-fold and 1.30-fold of
that from pure DZP sample and 1:3 DZP/MCM41 sample,
respectively. In heart and lung, the drug content of 1:3 DZP/
MCM41 sample and 1:3 DZP/CMS sample remained the high-
est, respectively. It is worth mentioning that, in brain, the
content of DZP from 1:3 DZP/CMS sample was 2.71-fold
higher than that at 45min postadministration and was 62.31-
fold and 7.72-fold of that from pure DZP sample and 1:3
DZP/MCM41 sample, respectively. This may contribute to the
treatment of anxiety and seizures. Moreover, at 90min post-
administration, remarkable distribution of DZP in spleen was
emerged from 1:3 DZP/CMS sample, which remained almost
the same drug content as at 45min postadministration, and
was 2.85-fold higher than the 1:3 DZP/MCM41 sample and
1.96-fold higher than the pure DZP sample. The drug accu-
mulated in spleen may play the role of drug reservoirs to
remain a higher DZP concentration. From these results, it
was speculated that DZP/CMS drug loading system had
altered the DZP biodistribution in mice and had the ten-
dency of brain targeting and lung targeting. Therefore, it is
reasonable to presume that the change of DZP biodistribu-
tion could be attributed to the presence of CMS, but not the
passive targeting effect of carriers or the decrease of DZP
particle size. However, the targeting mechanisms of CMS
should be further studied.
3.7. Pharmacodynamic study of NMS
Anti-inflammatory effects of NMS, 1:3 NMS/CMS and 1:3
NMS/MCM41 were systematically evaluated and compared by
mouse ankle swelling test, mouse ear swelling test and
mouse writhing test, and the results were shown in Figure 7
and Table 2, respectively. It can be seen that in Table 2, both
1:3 NMS/CMS and 1:3 NMS/MCM41 can obviously inhibit the
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ankle swelling, ear swelling and the acetic acid-induced
writhing in rats in comparison with pure NMS. Among them,
the anti-inflammatory effect of 1:3 NMS/CMS significantly
outperformed that of NMS and 1:3 NMS/MCM41.
3.7.1. Mouse ankle swelling test
Ankle swelling responses in each group at 0.5–4 h after injec-
tion were presented in Figure 7(A). In NS group (negative
control), maximum swelling (15.5%) was observed at 1 h, and
swelling gradually diminished thereafter. However, swelling
curves in other groups peaked at 0.5 h, and swelling began
to decrease spontaneously. Both NMS/CMS and NMS/MCM41
can obviously inhibit the ankle swelling degree compared to
the pure NMS. Under the same dose, NMS/CMS (NMS/CMS
middle-dose group, which maximum swelling rate was less
than 1.5%) had a stronger effect than NMS/MCM41. It should
be noticed that 1:3 NMS/CMS dose dependently and
significantly inhibited the swelling induced by carrageenan,
and almost no swelling was observed in NMS/CMS middle-
dose group and the NMS/CMS high-dose group and indi-
cated the activity of NMS/CMS in swelling inhibition.
3.7.2. Mouse ear swelling test
Mouse ear swelling test was carried out to further evaluate
the anti-inflammatory potential of 1:3 NMS/CMS and 1:3
NMS/MCM41, and the results were shown in Figure 7(B) and
Table 2, respectively. In the NS group, xylene caused signifi-
cant increase in ear weight, and the swelling rate was as
high as 67%. By application of NMS, a lower increase in ear
weight was observed, the swelling rate was 32.4%, and this
value was used as positive control. As can be seen from
Figure 7(B), CMS as well as MCM41 contributed to the inhib-
ition of swelling, and the inhibition rate was as high as
102.2% and 82.3%, respectively. The results demonstrated
Figure 6. DZP contents in blood, heart, liver, lung, spleen and kidney at (A) 45min; (B) 90min postadministration.
DRUG DELIVERY 1095
D
ow
nl
oa
de
d 
by
 [C
op
en
ha
ge
n U
niv
ers
ity
 L
ibr
ary
] a
t 0
2:2
7 2
5 S
ep
tem
be
r 2
01
7 
the enhancement of swelling inhibition activity of NMS by
incorporating into CMS or MCM41. It seemed that NMS/CMS
was found to be more powerful in suppressing ear swell in
mice compared to NMS/MCM41.
3.7.3. Mouse writhing test
The antinociceptive effects of NMS/CMS, NMS/MCM4 and
pure NMS were estimated by acetic acid-induced mouse
writhing test. Figure 7(C) and Table 2 showed the writhing
responses in mice, respectively. It can be seen that the num-
ber of writhes induced by acetic acid was significantly
reduced by administration of 1:3 NMS/CMS due to the
improvement of pain threshold in mice, and the inhibition
rate was as high as 312.1%. 1:3 NMS/MCM41 had a weaker
antinociceptive effect than NMS/CMS, the inhibition rate was
134.5% which was also stronger than that of pure NMS, and
the average number of writhes was reduced from 103.7
(negative control) to 81.7.
The results demonstrated that after loading into CMS, the
swelling inhibition effect and analgesic activity of NMS were
significantly enhanced. Moreover, NMS/CMS showed dose-
related inhibitory effect on ankle swelling of mouse.
4. Conclusions
In summary, proline-derivative templated mesoporous silica
spheres with a large number of curved channels were biomi-
metically synthesized in water solvent using CSDA method
and were successfully developed as an effective nanocarrier
to improve the drug release behavior and the bioavailability
of poorly water-soluble drugs. During this process, the
curved mesostructural was induced by the dynamic behavior
of N-palmitoyl-L-proline and imprinted along with the silica
deposition procedure. Drugs can be incorporated into CMS
with high efficiency and drugs transformed from crystalline
state to amorphous state due to the space confinement. As a
Table 2. Inhibition rate (%) of NMS-CMS 3:1 and NMS-MCM41 3:1 in MAST, MEST and MWT.
Inhibition rate (%)
MAST
Sample 0.5 h 1 h 1.5 h 2 h 3 h 4 h MEST MWT
1:3 NMS/CMS 904.3 ± 101.1 328.7 ± 29.1 244.2 ± 40.4 167.3 ± 16.2 180.0 ± 20.0 175.0 ± 25.5 102.2 ± 14.5 312.1 ± 62.0
1:3 NMS-MCM41 698.1 ± 97.0 318.9 ± 2.6 260.1 ± 20.8 133.2 ± 16.7 59.7 ± 19.9 58.2 ± 38.8 82.3 ± 21.7 134.5 ± 60.9
Figure 7. Anti-inflammatory analgesic effects of samples. (A) The anti-inflammatory effects of NMS formulations on mouse ankle swelling induced by carrageenan;
(B) the effects on mouse ear swelling caused by xylene; (C) the analgesic effects of samples on acetic acid-induced writhing in mice.
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result, the dissolution rates of the drugs were significantly
improved. The biodistribution study suggested that, after
loaded into CMS, the DZP distribution in mice had been
altered and showed the tendency of brain targeting and
lung targeting. In particular, we will focus on the targeting
mechanisms of CMS in vivo in the next step. Besides, the
pharmacodynamic experiment demonstrated that the anti-
inflammation effect and analgesia action of NMS were obvi-
ously improved by incorporating into CMS, which undoubt-
edly favored the clinical treatment.
We believe that these findings will provide useful informa-
tion on biological application of CMS and are of great
importance for controlled drug delivery and release system
of nanoporous silica-based drug carriers.
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